Skip to content

Clinical Observation of Yiqi Huoxue Jiedu herbs in Improving the Prognosis of Stable Coronary Heart Disease

Clinical Observation of Yiqi Huoxue Jiedu herbs in Improving the Prognosis of Stable Coronary Heart Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023057
Enrollment
Unknown
Registered
2019-05-09
Start date
2019-05-08
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable Coronary Heart Disease

Interventions

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria for stable coronary heart disease 2.Aged between 18-75 years 3.Meets the criteria of moderate or severe angina (CCS classification II, III) or meets at least 2 conditions in 4 conditions including Hs-CRP>3mg/L, high blood pressure (classification II-III), high cholesterol history, and diabetes history 4.singed the consent form

Exclusion criteria

Exclusion criteria: 1. Combined with other heart diseases, or severe cardiopulmonary insufficiency (heart function level III or higher, severe pulmonary insufficiency); 2. Combined with Acute cerebrovascular disease; 3. Combined with uncontrolled blood pressure(systolic blood pressure =160mmHg and diastolic blood pressure =100mmHg); 4. Combined with malignant arrhythmia (ventricular tachycardia, supraventricular arrhythmia affecting hemodynamics) which repeated attacks recently; 5. Combined with severe primary diseases such as liver, kidney, and hematopoietic system, acute infectious diseases, and mental illness; 6. Pregnant, planning to get pregnant or lactating women; 7. Have done head, chest and abdominal operation and bleeding tendency in the past 4 week; 8. Participated in other clinical trials in the past 1 month; 9. Allergic constitution or allergic to the known ingredients of the test drug.

Design outcomes

Primary

MeasureTime frame
Cardiac death;Non-fatal myocardial infarction;Repeated revascularization;

Secondary

MeasureTime frame
All-cause death;Hospitalized for acute myocardial infarction/heart failure/malignant arrhythmia;Cerebral ischemic stroke;Other thrombotic complications;

Countries

China

Contacts

Public ContactDazhuo Shi

Xiyuan Hospital, China Academy of Chinese Medical Sciences

shidazhuo@126.com+86 13911972856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026